Prosus will score an exit today when data analytics platform developer Similarweb floats in the US following $240m in earlier funding.

MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.

Cambridge’s gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.

The Meituan Dianping, Tencent and Swiss Re-backed health insurance marketplace operator priced its offering at the top of its range.

Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.

The Alibaba and Telstra-backed cloud services provider has filed to float in the United States having raised a reported $445m in the past five years.

The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.

The Taiho and UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.

The cybersecurity technology provider, which counts SB Isat among its early investors, has gone public in its home country.